|
07.12.2021 15:23:44
|
Anixa : COVID-19 Compounds Expected To Be Effective Against Omicron And Delta Variants
(RTTNews) - Anixa Biosciences Inc. (ANIX) and MolGenie said that their COVID-19 compounds are expected to be effective against the Omicron Variant as well as the Delta variant.
The companies noted that they are developing compounds for the potential treatment of COVID-19 with the long-term goal of developing an inexpensive, orally-administered room temperature-stable pill for the outpatient setting.
The program focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the SARS-CoV-2 virus, which is necessary for replication.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Anixa Biosciences Inc Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Anixa Biosciences Inc Registered Shsmehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.